Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "FNSGp"

From Bioblast
Line 10: Line 10:
This substrate combination supports convergent electron flow to the [[Q-junction]].
This substrate combination supports convergent electron flow to the [[Q-junction]].


|info=[[MiPNet21.06 SUIT reference protocol]], [[Gnaiger 2014 MitoPathways]]
|info=[[MiPNet21.06 SUIT reference protocol]], [[Gnaiger 2020 BEC MitoPathways]]
}}
{{MitoPedia concepts
|mitopedia concept=SUIT state
}}
}}
::: ''More details'' Β 
::: ''More details'' Β 
Line 43: Line 40:
[[File:SUIT-Reference-Protocol 2.jpg|700px |SUIT RP2]]
[[File:SUIT-Reference-Protocol 2.jpg|700px |SUIT RP2]]
----
----
{{MitoPedia concepts
|mitopedia concept=SUIT state
}}

Revision as of 19:57, 1 January 2021


high-resolution terminology - matching measurements at high-resolution


FNSGp

Description

Convergent electron flow

MitoPathway control state: FNSGp

Octanoylcarnitine or Palmitoylcarnitine & Pyruvate &/or Glutamate & Malate & Succinate & Glycerophosphate.

SUIT protocol: SUIT-002

This substrate combination supports convergent electron flow to the Q-junction.

Abbreviation: FNSGp

Reference: MiPNet21.06 SUIT reference protocol, Gnaiger 2020 BEC MitoPathways

More details
Β» Additive effect of convergent electron flow
Β» Respiratory complexes - more than five
Β» OctPGMSGp pathway control state
Β» Convergent electron flow


FNSGpL

FNSGp pathway in the LEAK state can be evaluated in the following SUIT protocols:

FNSGpP

FNSGp pathway in the OXPHOS state can be evaluated in the following SUIT protocols:

FNSGpE

FNSGp pathway in the ET state can be evaluated in the following SUIT protocols:



SUIT RP2



MitoPedia concepts: SUIT state